```
Trying 3106016892...Open

Welcome to STN International!  Enter x:x
LOGINID:ssspta1619lxw
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1           Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2  Dec 17   The CA Lexicon available in the CAPLUS and CA files
 NEWS  3  Feb 06   Engineering Information Encompass files have new names
 NEWS  4  Feb 16   TOXLINE no longer being updated
 NEWS  5  Apr 23   Search Derwent WPINDEX by chemical structure
 NEWS  6  Apr 23   PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA
 NEWS  7  May 07   DGENE Reload
 NEWS  8  Jun 20   Published patent applications (A1) are now in USPATFULL
 NEWS  9  JUL 13   New SDI alert frequency now available in Derwent's
                   DWPI and DPCI
 NEWS 10  Aug 23   In-process records and more frequent updates now in
                   MEDLINE
 NEWS 11  Aug 23   PAGE IMAGES FOR 1947-1966 RECORDS IN CAPLUS AND CA
 NEWS 12  Aug 23   Adis Newsletters (ADISNEWS) now available on STN
 NEWS 13  Sep 17   IMSworld Pharmaceutical Company Directory name change
                   to PHARMASEARCH

 NEWS EXPRESS  August 15 CURRENT WINDOWS VERSION IS V6.0c,
               CURRENT MACINTOSH VERSION IS V6.0 (ENG) AND V6.0J (JP),
               AND CURRENT DISCOVER FILE IS DATED 07 AUGUST 2001
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *



FILE 'HOME' ENTERED AT 14:56:18 ON 24 SEP 2001

=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.15       0.15

FILE 'REGISTRY' ENTERED AT 14:56:28 ON 24 SEP 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
```

COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 23 SEP 2001 HIGHEST RN 358331-51-8
DICTIONARY FILE UPDATES: 23 SEP 2001 HIGHEST RN 358331-51-8

TSCA INFORMATION NOW CURRENT THROUGH January 11, 2001

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT for details.

```
=> s soya peptide
          652 SOYA
        57495 PEPTIDE
L1          0 SOYA PEPTIDE
                (SOYA(W)PEPTIDE)

=> s phytokine
L2          1 PHYTOKINE

=> s kollaren ccp
            1 KOLLAREN
           40 CCP
L3          0 KOLLAREN CCP
                (KOLLAREN(W)CCP)

=> fil caplus uspatfull embase kosmet biosis
COST IN U.S. DOLLARS                        SINCE FILE      TOTAL
                                              ENTRY    SESSION
FULL ESTIMATED COST                           19.93      20.08

FILE 'CAPLUS' ENTERED AT 14:58:09 ON 24 SEP 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 14:58:09 ON 24 SEP 2001
CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 14:58:09 ON 24 SEP 2001
COPYRIGHT (C) 2001 Elsevier Science B.V. All rights reserved.

FILE 'KOSMET' ENTERED AT 14:58:09 ON 24 SEP 2001
COPYRIGHT (C) 2001 International Federation of the Societies of Cosmetics
Chemists

FILE 'BIOSIS' ENTERED AT 14:58:09 ON 24 SEP 2001
COPYRIGHT (C) 2001 BIOSIS(R)

=> fil l2 or soya peptide or kollaren ccp
'L2' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available. If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):end

=> 2 l2 or soya peptide or kollaren ccp.
```

```
2 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l2 or soya peptide or kollaren ccp
L4          13 L2 OR SOYA PEPTIDE OR KOLLAREN CCP

=> dup rem l4
DUPLICATE IS NOT AVAILABLE IN 'KOSMET'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L4
L5           11 DUP REM L4 (2 DUPLICATES REMOVED)

=> d ibib abs

L5   ANSWER 1 OF 11  CAPLUS  COPYRIGHT 2001 ACS
ACCESSION NUMBER:         2000:240911  CAPLUS
DOCUMENT NUMBER:          132:269849
TITLE:                    Cosmetic composition comprising anti-striae peptides
                          for the prevention and/or treatment of skin striae
INVENTOR(S):              Msika, Philippe
PATENT ASSIGNEE(S):       Laboratoires Pharmascience, Fr.
SOURCE:                   PCT Int. Appl., 30 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 French
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
     WO 2000019974      A1   20000413       WO 1999-FR2375   19991005
         W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
             CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
             IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,
             MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
             SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
             DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
             CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     FR 2784029         A1   20000407       FR 1998-12435    19981005
     FR 2784029         B1   20010105
     AU 9959894         A1   20000426       AU 1999-59894    19991005
PRIORITY APPLN. INFO.:                   FR 1998-12435    A  19981005
                                         WO 1999-FR2375   W  19991005
AB   The invention concerns a method for prevention and/or cosmetic treatment
     of skin striae, characterized in that it consists in applying on the
zones
     likely to form or already affected by striae a compn. comprising, in an
     appropriate excipient, at least an anti-striae agent selected among the
     group consisting of soya bean peptides, tripeptides formed with glycine,
     histidine and lysine amino acids, and the mixts. thereof.  The invention
     concerns the use of said compn. in dermatol.  It enables to prevent
and/or
     treat skin striae efficiently and is acceptable as far as skin tolerance
     is concerned.  An anti-striae cream contained cetyl dimethicone 2, octyl
     sebacate 5, isononyl isononanoate 7, Cutina CBS 2.5, Me paraben 0.1, Pr
     paraben 0.1, PEG-300 5, triethanolamine 4.8, Sepigel-305 5.5, Phytokine
2,
```

lactic acid 10, Enteline-2 0.4, sophora japonica 3, methylsilanol lactate 3, zinc gluconate 0.2, copper gluconate 0.2, perfume 0.35, and water q.s. 100%. Efficacy of the compn. in the treatment of skin striae was shown.
REFERENCE COUNT: 2
REFERENCE(S): (1) Moy, L; US 5759555 A 1998 CAPLUS
(2) Rapaport, J; US 5444091 A 1995 CAPLUS

=> d 2 ibib abs

L5 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 2000:542381 CAPLUS
DOCUMENT NUMBER: 133:136817
TITLE: Surface treated inorganic or organic powders
INVENTOR(S): Hyodo, Shoji
PATENT ASSIGNEE(S): Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 3 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000219820	A2	20000808	JP 1999-59167	19990129

AB The surfaces of (in)org. powders having a diam. of 0.01-50 .mu.m are treated with 0.1-5.0% polypeptide (derivs.) to improve the dispersibility.
Stirring 5 kg TiO2 powders at 3,000 rpm and spraying with a mixt. of 400-g water and 100-g **soya peptide**, drying in vacuo, and pulverizing gave powders easily dispersed in polar solvent and/or org. solvent-based matrix.

=> d 3 ibib abs

L5 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1999:244556 CAPLUS
DOCUMENT NUMBER: 130:301685
TITLE: Peptide/lipid complex formation by co-lyophilization
INVENTOR(S): Dasseux, Jean-Louis
PATENT ASSIGNEE(S): USA
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9917740	A1	19990415	WO 1998-US20330	19980928

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,

FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6287590	B1	20010911	US 1997-942597	19971002
AU 9896715	A1	19990427	AU 1998-96715	19980928
EP 1019025	A1	20000719	EP 1998-950743	19980928
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
NO 2000001683	A	20000510	NO 2000-1683	20000331

PRIORITY APPLN. INFO.: US 1997-942597 A 19971002
WO 1998-US20330 W 19980928

AB The invention relates to the formation of peptide/lipid vesicles and complexes through the co-lyophilization of peptides, preferably that are able to adopt an amphipathic .alpha.-helical conformation, and one or more lipids. A single soln. which solubilizes both the peptides and lipids or two sep. solns. may be lyophilized. The methods are used to generate stable peptide/lipid vesicles and complexes including micellar, spherical, and discoidal complexes in bulk prepns. and in smaller units, as may be suitable for dosage forms. Peptide 1 (PVLDLFRELLNELLEALKQKLK) was dissolved in methanol at a concn. of 3.5 mg/mL by incubation for several mins. and mixing by vortex intermittently. To this soln. was added dipalmitoylphosphatidylcholine (DPPC) in methanol (100 mg/mL) such that the final ratio of DPPC/peptide was 2.5:1. Xylene was added to the soln. to a final concn. of 36 %. The soln. was freeze-dried and an aliquot contg. 20 mg peptide 1 and 50 mg DPPC was rehydrated in a saline soln., mixed, and heated to 41.degree. until a clear soln. of reconstituted peptide/phospholipid complexes resulted.

REFERENCE COUNT: 2
REFERENCE(S): (1) Lerch; US 5652339 A 1997 CAPLUS
(2) Nedelec, J; Biochimie 1989, V71, P145 CAPLUS

=> d 4 ibib abs

L5 ANSWER 4 OF 11 USPATFULL

ACCESSION NUMBER: 1998:17293 USPATFULL
TITLE: Derivative of caffeic acid, oraposide, and cosmetic or pharmaceutical compositions, in particular dermatological compositions, containing it
INVENTOR(S): Andary, Claude, Montpellier Cedex, France
Andre, Patrice, Neuvilles aux Bois, France
PATENT ASSIGNEE(S): Parfums Christian Dior, Paris, France (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5719129		19980217	
	WO 9216544		19921001	
APPLICATION INFO.:	US 1993-119172		19931015	(8)
	WO 1991-FR229		19910321	
			19931015	PCT 371 date
			19931015	PCT 102(e) date

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Peselev, Elli
LEGAL REPRESENTATIVE: Foley & Lardner
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 2 Drawing Page(s)

LINE COUNT: 713
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a new derivative of caffeic acid.

This new derivative has the formula I below: ##STR1## in which one or more R independently represent a hydrogen atom, a C.sub.1 -C.sub.5 alkyl group, in particular methyl, and an acyl group, in particular a C.sub.1 -C.sub.6 group, in particular acetyl.

This new derivative called oraposide is particularly useful for the preparation of cosmetic or pharmaceutical compositions, in particular dermatological compositions, as a result in particular of its activity against free radicals, inflammation and aging due to radiation exposure.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 5 ibib abs

L5 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2001 ACS DUPLICATE 1
ACCESSION NUMBER: 1998:390763 CAPLUS
DOCUMENT NUMBER: 129:173454
TITLE: Activation of fibroblast metabolism in a dermal and skin equivalent model: a screening test for activity of peptides
AUTHOR(S): Frei, V.; Perrier, E.; Orly, I.; Huc, A.; Augustin, C.; Damour, O.
CORPORATE SOURCE: COLETICA, Lyon, Fr.
SOURCE: Int. J. Cosmet. Sci. (1998), 20(3), 159-173
CODEN: IJCMDW; ISSN: 0142-5463
PUBLISHER: Chapman & Hall
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Skin firmness, elasticity and tone are gradually lost with age. These changes originate in the dermis and correspond to a decrease in the ability of cells, particularly the fibroblasts, to regenerate the mols. which make up the extracellular matrix. Skin aging is also characterized by a redn. of the epidermal thickness and by a flattening of the basal membrane. The recent development of two 3-dimensional culture systems, in which the cells develop within a porous structure reproducing the extracellular matrix of the human dermis, is a way of reproducing in vivo conditions and demonstrating the biol. effects of anti-aging compds. The dermal equiv. model used in this study is composed of a dermal matrix made of collagen-chitosan-glycosaminoglycans populated by normal human fibroblasts which synthesized their own extracellular matrix. A skin equiv. model is obtained by the cell culture of normal human keratinocytes onto a dermal equiv. elevated at the air-liq. interface. Such models were used to prove anti-ageing activity of promising compds. Cosmetic science has used many protein hydrolyzates in order to fight skin ageing, but up to now, these natural peptides were poorly studied, and their efficacy poorly demonstrated. Eight protein hydrolyzates were screened in a proliferation study in monolayered cultures giving two selected polypeptides. A soya derived peptide was used for an efficiency study in 3-dimensional models. In the dermal equiv. model, this peptide increased

fibroblast proliferation by 40% and led to a stimulation of collagen formation (+65%) and elastin (+16%) synthesis. The effect of this **soya peptide** on glycosaminoglycan synthesis was also significant, with increases of 36% for chondroitin-4-sulfate and 68% for hyaluronic acid. These results were confirmed using a skin equiv. model. In this model, the **soya peptide** increased the thickness of the epidermis.

=> d 5 kwic

L5 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2001 ACS DUPLICATE 1
AB . . . . proliferation by 40% and led to a stimulation of collagen formation (+65%) and elastin (+16%) synthesis. The effect of this **soya peptide** on glycosaminoglycan synthesis was also significant, with increases of 36% for chondroitin-4-sulfate and 68% for hyaluronic acid. These results were confirmed using a skin equiv. model. In this model, the **soya peptide** increased the thickness of the epidermis.

=> d 6 ibib abs

L5 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1997:630750 CAPLUS
DOCUMENT NUMBER: 127:326571
TITLE: Anti-alopecia agents
INVENTOR(S): Yoshikawa, Masaaki; Takahata, Chikanari; Takatsuji, Masao; Yamada, Tadakazu
PATENT ASSIGNEE(S): Honen Corp., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09249535	A2	19970922	JP 1996-84667	19960313

AB Anti-alopecia agents contain soya peptides i.e. Met-Ile-Thr-Leu-Ala-Ile-Pro-Val-Asn-Lys-Pro-Gly-Arg, Met-Ile-Thr-Leu-Ala-Ile-Pro-Val-Asn-Lys-Pro-Gly, Met-Ile-Thr-Leu-Ala-Ile-Pro-Val-Asn-Lys-Pro, Met-Ile-Thr-Leu-Ala-Ile-Pro-Val-Asn-Lys, Met-Ile-Thr-Leu-Ala-Ile-Pro-Val-Asn, Met-Ile-Thr-Leu-Ala-Ile-Pro-Val, Met-Ile-Thr-Leu-Ala-Ile-Pro, Met-Ile-Thr-Leu-Ala-Ile, Met-Ile-Thr-Leu-Ala, Met-Ile-Thr-Leu-Ala, and/or Met-Ile-Thr-Leu. The soya peptides can be incorporated into injections or other drug delivery systems. Effectiveness was tested in an exptl. male rat model.

=> d 7 ibib abs

L5 ANSWER 7 OF 11 USPATFULL
ACCESSION NUMBER: 97:24738 USPATFULL
TITLE: Cosmetic composition for the simultaneous treatment of the surface and deep layers of the skin, its use
INVENTOR(S): Ribier, Alain, Paris, France
Simonnet, Jean-Thierry, Paris, France

PATENT ASSIGNEE(S): L'Oreal, Paris, France (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5614215		19970325	
APPLICATION INFO.:	US 1994-366723		19941230	(8)

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1993-15863	19931230

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Kishore, Gollamudi S.
LEGAL REPRESENTATIVE: Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
LINE COUNT: 645
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A composition comprising a first dispersion of lipid vesicles capable of entering the deep layers of the skin and containing at least one first active substance capable of treating these deep layers, and a second dispersion of lipid vesicles capable of entering the surface layers of the skin and containing at least one second active substance, different from the first active substance, capable of treating these surface layers is found effective for anti-age, anti-wrinkle, depigmenting, nutrient, slimming, hydrating, anti-ache, antimycotic, anti-dermic and anti-psoriatic treatment.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d 8 ibib abs

L5 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1992:549463 CAPLUS
DOCUMENT NUMBER: 117:149463
TITLE: Manufacture of peptide mixtures and beverages containing them
INVENTOR(S): Kimoto, Minoru; Matsui, Masayuki; Nakamori, Toshihiro; Matsuo, Takaaki
PATENT ASSIGNEE(S): Fuji Oil Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 04190797	A2	19920709	JP 1990-326585	19901127

AB Peptide mixts. are manufd. by (i) centrifuging hydrolyzate (obtained by enzymic decompn. of vegetable proteins with endoprotease) in acidic water system to remove ppt. and (ii) subsequently treating with anion-exchange resins. Beverages contg. 0.1-50 wt.% peptide mixts have good flavor, are ppt.-free, and do not discolor. Thus, 10% aq. soln. (pH 7) of 1 kg Fujipro R (sepd. soybean protein) was hydrolyzed with Protin AC-10 (endoprotease) at 50.degree. for 5 h, then the enzyme was inactivated.

The pH was adjusted to 4.0 and the soln. was centrifuged to remove the ppt., which (50 kg) was treated with KA-890 (weakly basic anion-exchange resin) and filtered to give a soln. The soln. (10 kg) was treated with HP-20 (hydrophobic adsorbent), filtered, and dried to give 210 g peptide mixt. The peptide mixt. 20, sucrose 60, and citric acid 1.2 g were mixed to adjust the pH to 3.8, and further mixed with orange, lemon, and pineapple flavors to give a beverage.

=> d 8 kwic

L5 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2001 ACS
IT Protein hydrolyzates
RL: BIOL (Biological study)
(**soya**, **peptide** mixts. manuf. from, with endoprotease, for beverage manuf.)

=> d 9 ibib abs

L5 ANSWER 9 OF 11 USPATFULL

ACCESSION NUMBER:	78:784 USPATFULL		
TITLE:	Process for extracting a polypeptide from an aqueous solution		
INVENTOR(S):	Schneider, Michel, Grand-Lancy, Switzerland		
PATENT ASSIGNEE(S):	Battelle Memorial Institute, Switzerland (non-U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4066505		19780103
APPLICATION INFO.:	US 1976-667258		19760316 (5)
	NUMBER		DATE
PRIORITY INFORMATION:	CH 1975-3468		19750318
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Shapiro, Lionel M.		
LEGAL REPRESENTATIVE:	Burns, Robert E., Lobato, Emmanuel J., Adams, Bruce L.		
NUMBER OF CLAIMS:	8		
EXEMPLARY CLAIM:	1		
LINE COUNT:	418		

AB A polypeptide is extracted from an aqueous solution by a process in which a water-soluble macromolecular complex (I) of macromolecules covalently boned to molecules of at least one compound capable of fixing the polypeptide in a selective, reversible and non-destructive manner, is selectively reacted with the polypeptide in the solution to fix the polypeptide by forming in solution a complex (II); and the complex (II) is separated from the solution and dissociated into polypeptide molecules and complex (I) molecules, and the polypeptide is isolated.

=> d 9 kwic

L5 ANSWER 9 OF 11 USPATFULL
CLM What is claimed is:
. . . in which the said molecules are molecules selected from the group

comprising p-aminobenzoic acid, o-aminobenzoic acid, trypsin, N-.omega.-aminohexyl-L-aspartic acid, trypsin-inhibiting **soya peptide**, p-aminophenyl-thiogalactoside, poly-L-lysine, nicotinamide adenine dinucleotide (NAD) and D-asparagine.

=> d 10 ibib abs

L5 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2001 ACS
ACCESSION NUMBER: 1979:20965 CAPLUS
DOCUMENT NUMBER: 90:20965
TITLE: The determination of soya protein in meat products using peptide analysis and the characterization of the specific **soya peptide** used in the calculations
AUTHOR(S): Bailey, Frank J.; Llewellyn, Jeffery W.; Hitchcock, Christopher H. S.; Dean, Ann C.
CORPORATE SOURCE: Unilever Res. Lab., Sharnbrook, Engl.
SOURCE: Chem. Ind. (London) (1978), (13), 477-8
CODEN: CHINAG; ISSN: 0009-3068
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The structure of SP-1, the soya-specific peptide used in the title anal., and the protein source in the soya were detd. for digests of 3 main soya protein fractions by ion-exchange chromatog. The SP-1 peaks were heterogeneous, consisting of one main component and .gtoreq.7 minor ones and the cor. amino acid values matched a peptide contg. 1 serine residue, 2 glutamic acid residues, 1 alanine, and 1 arginine residue. The results were consistent with those obtained using known anal. techniques and showed that the arginine peptide was the main component of SP-1 and it originated from the 11S protein fraction of soya bean.

=> d 11 ibib abs

L5 ANSWER 11 OF 11 KOSMET COPYRIGHT 2001 IFSCC
ACCESSION NUMBER: 20509 KOSMET
FILE SEGMENT: scientific, technical
TITLE: ACTIVATION OF FIBROBLAST METABOLISM IN A DERMAL AND SKIN EQUIVALENT MODEL: A SCREENING TEST FOR ACTIVITY OF PEPTIDES
AUTHOR: FREI V (COLETICA, 32, RUE SAINT JEAN DE DIEU, LYON, FRANCE); PERRIER E; ORLY I; HUC A; AUGUSTIN C; DAMOUR O
SOURCE: PRESENTED AT THE 19TH IFSCC CONGRESS IN SYDNEY, 22-25 OCTOBER 1996, INT J.COSMET SCI, 1998, 20, 3, 159-173, 26 REFS
LANGUAGE: English
AN 20509 KOSMET FS scientific, technical
AB Skin firmness, elasticity and tone are gradually lost with age. These changes originate in the dermis and correspond to a decrease in the ability of cells, particularly the fibroblasts, to regenerate the molecules which make up the extracellular matrix. Skin ageing is also characterized by a reduction of the epidermal thickness and by a flattening of the basal membrane. The recent development of two 3-dimensional culture systems, in which the cells develop within a porous structure reproducing the extracellular matrix of the human dermis, is a

way of reproducing in vivo conditions and demonstrating the biological effects of anti-ageing compounds. The dermal equivalent model used in this study is composed of a dermal matrix made of collagen-chitosan-glycosaminoglycans populated by normal human fibroblasts which synthesized their own extracellular matrix. A skin equivalent model is obtained by the cell culture of normal human keratinocytes onto a dermal equivalent elevated at the air-liquid interface. Such models were used to prove anti-ageing activity of promising compounds. Cosmetic Science has used many protein hydrolysates in order to fight skin ageing, but up to now, these natural peptides were poorly studied, and their efficacy poorly demonstrated. Eight protein hydrolysates were screened in a proliferation study in monolayered cultures giving two selected polypeptides. A soya derived peptide was used for an efficiency study in 3-dimensional models. In the dermal equivalent model, this peptide increased fibroblast proliferation by 40% and led to a stimulation of collagen formation (+65%) and elastin (+16%) synthesis. The effect of this **soya peptide** on glycosaminoglycan synthesis was also significant, with increases of 36% for chondroitin-4-sulfate and 68% for hyaluronic acid. These results were confirmed using a skin equivalent model. In this model, the **soya peptide** increased the thickness of the epidermis

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	37.24	57.32

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.70	-4.70

* *

Dear valued customer,

Your feedback is important to us. Would you kindly take a moment to complete our survey? This survey will only take about 5-10 minutes to complete. Your responses will be kept confidential and will help us improve STN Express with Discover! for your future use. Please click on the following link to access the survey.

http://www.cas.org/ONLINE/STN/ExpressSurveyForm.html?LOGINID=SSSPTA1619LXW

* *

STN INTERNATIONAL LOGOFF AT 15:05:44 ON 24 SEP 2001

WEST

Freeform Search

Database: US Patents Full-Text Database; US Pre-Grant Publication Full-Text Database; JPO Abstracts Database; EPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Term: enteromorpha compressa or chlorophycea or enteline 2

Display: 10 **Documents in Display Format:** CIT **Starting with Number** 1

Generate: ○ Hit List ◉ Hit Count ○ Image

Search | Clear | Help | Logout | Interrupt

Main Menu | Show S Numbers | Edit S Numbers | Preferences

Search History

Today's Date: 9/24/2001

DB Name	Query	Hit Count	Set Name
USPT,PGPB,DWPI	l30 and l17	0	L31
USPT,PGPB,DWPI	l6 and l7	131	L30
USPT,PGPB,DWPI	l10 and l18	0	L29
USPT,PGPB,DWPI	l10 and l17	0	L28
USPT,PGPB,DWPI	l10 and l16	0	L27
USPT,PGPB,DWPI	l10 and l15	0	L26
USPT,PGPB,DWPI	l10 and l15 and l16	0	L25
USPT,PGPB,DWPI	l22 and l16	0	L24
USPT,PGPB,DWPI	l22 and l15	0	L23
USPT,PGPB,DWPI	l10 and l14	26	L22
USPT,PGPB,DWPI	l10 and l13	49	L21
USPT,PGPB,DWPI	l18 and l16 and l15 and l13	3	L20
USPT,PGPB,DWPI	l18 and l16 and l15 and l13	3	L19
USPT,PGPB,DWPI	sophora japonica or methylsilaryl lactate or copper gluconate or zinc gluconate	630	L18
USPT,PGPB,DWPI	enteromorpha compressa or chlorophycea or enteline 2	10	L17
USPT,PGPB,DWPI	neuropeptide y or neuropeptide-y	638	L16
USPT,PGPB,DWPI	substance p or substance-p	2855	L15
USPT,PGPB,DWPI	lactic acid	33291	L14
USPT,PGPB,DWPI	alpha hydroxy acid or citric or pyruvic or glycolic or lactic	107663	L13
USPT,PGPB,DWPI	(tripeptide) and (glycine near histidine near lysine)	12	L12
USPT,PGPB,DWPI	soya peptide or phytokine or kollaren cpp or kollaren-cpp	4	L11
USPT,PGPB,DWPI	stretchmark or stretch mark	222	L10
USPT	sophora japonica or methylsilaryl lactate or copper gluconate or zinc gluconate	457	L9
USPT	enteromorpha compressa or chlorophycea or enteline 2	5	L8
USPT	neuropeptide y or neuropeptide-y	455	L7
USPT	substance p or substance-p	2213	L6
USPT	lactic acid	24925	L5
USPT	alpha hydroxy acid or citric or pyruvic or glycolic or lactic	81413	L4
USPT	(tripeptide) and (glycine near histidine near lysine)	10	L3
USPT	soya peptide or phytokine or kollaren cpp or kollaren-cpp	3	L2
USPT	stretchmark or stretch mark	148	L1

WEST

Generate Collection

L17: Entry 8 of 10 File: DWPI Jan 25, 1980

DERWENT-ACC-NO: 1980-16935C
DERWENT-WEEK: 198010

TITLE: Culture of phytoplankton in sea water - enriched with minerals, vitamin(s) and aminoacid(s), used in cosmetics and in human and veterinary medicine

INVENTOR: BREVIER, J

PATENT-ASSIGNEE:

ASSIGNEE	CODE
BREVIER J	BREVI

PRIORITY-DATA: 1978FR-0015678 (May 26, 1978)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
FR 2426404 A	January 25, 1980	N/A	000	N/A

INT-CL (IPC): A01G 33/02; A23K 1/18

ABSTRACTED-PUB-NO: FR 2426404A

BASIC-ABSTRACT:

Phytoplankton of the unicellular flagellate algae family chlorophycea, esp. chlorella SP is cultivated in a process in which sea-water is enriched with minerals, vitamins, and amino acids, seeded with the phytoplankton, and kept under proper conditions of temp., aeration and light for development. The culture is then successively transplanted after development.

In the first phase; culture is effected in a 500 ml. Erlenmeyer flask, and when the concn. of cells reaches 4 million/ml. it is passed to the second stage. This takes place in a 5 litre vessel. Illumination may be continuous or discontinuous and the temp. is kept at around 20 degrees C. When the flask contents reach satn. point, as far as phytoplankton development is concerned, which usually takes about 5 days, the culture may be continued in a larger vessel.

TITLE-TERMS: CULTURE PHYTOPLANKTON SEA WATER ENRICH MINERAL VITAMIN AMINOACID COSMETIC HUMAN VETERINARY MEDICINE

DERWENT-CLASS: B04 C03 D16 D21 P13

CPI-CODES: B04-B02B; B11-A; C04-B02B; C11-A; D05-H01; D08-B;

CHEMICAL-CODES:

Chemical Indexing M1 *01*
Fragmentation Code
V500 V550 N130 M720 M423 M902

Chemical Indexing M1 *02*
Fragmentation Code
V500 V550 N130 M720 M423 M902